186 related articles for article (PubMed ID: 21539451)
1. Influence of short polyglutamine tracts and p160 coactivators on the transactivation of the androgen receptor.
Shi XB; Xue L; Shi D; deVere White RW
Cancer Biother Radiopharm; 2011 Apr; 26(2):191-201. PubMed ID: 21539451
[TBL] [Abstract][Full Text] [Related]
2. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
[TBL] [Abstract][Full Text] [Related]
3. Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells.
Shi XB; Xue L; Zou JX; Gandour-Edwards R; Chen H; deVere White RW
Prostate; 2008 Dec; 68(16):1816-26. PubMed ID: 18780293
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length.
Irvine RA; Ma H; Yu MC; Ross RK; Stallcup MR; Coetzee GA
Hum Mol Genet; 2000 Jan; 9(2):267-74. PubMed ID: 10607837
[TBL] [Abstract][Full Text] [Related]
5. The antiandrogen bicalutamide activates the androgen receptor (AR) with a mutation in codon 741 through the mitogen activated protein kinase (MARK) pathway in human prostate cancer PC3 cells.
Terakawa T; Miyake H; Kumano M; Sakai I; Fujisawa M
Oncol Rep; 2010 Nov; 24(5):1395-9. PubMed ID: 20878136
[TBL] [Abstract][Full Text] [Related]
6. Involvement of three glutamine tracts in human androgen receptor transactivation.
Harada N; Mitani T; Higashimura Y; Yamaji R; Okamoto K; Nakano Y; Inui H
J Steroid Biochem Mol Biol; 2010 Jan; 118(1-2):77-84. PubMed ID: 19833203
[TBL] [Abstract][Full Text] [Related]
7. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor.
Masiello D; Cheng S; Bubley GJ; Lu ML; Balk SP
J Biol Chem; 2002 Jul; 277(29):26321-6. PubMed ID: 12015321
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of androgen receptor corepression by CKβBP2/CRIF1, a multifunctional transcription factor coregulator expressed in prostate cancer.
Tan JA; Bai S; Grossman G; Titus MA; Harris Ford O; Pop EA; Smith GJ; Mohler JL; Wilson EM; French FS
Mol Cell Endocrinol; 2014 Jan; 382(1):302-313. PubMed ID: 24103312
[TBL] [Abstract][Full Text] [Related]
9. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
10. Non-steroidal antiandrogens act as AF-1 agonists under conditions of high androgen-receptor expression.
Fuse H; Korenaga S; Sakari M; Hiyama T; Ito T; Kimura K; Kato S
Prostate; 2007 May; 67(6):630-7. PubMed ID: 17342748
[TBL] [Abstract][Full Text] [Related]
11. Characterization of allosteric modulators that disrupt androgen receptor co-activator protein-protein interactions to alter transactivation-Drug leads for metastatic castration resistant prostate cancer.
Fancher AT; Hua Y; Close DA; Xu W; McDermott LA; Strock CJ; Santiago U; Camacho CJ; Johnston PA
SLAS Discov; 2023 Oct; 28(7):325-343. PubMed ID: 37549772
[TBL] [Abstract][Full Text] [Related]
12. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
Hodgson MC; Astapova I; Hollenberg AN; Balk SP
Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
[TBL] [Abstract][Full Text] [Related]
13. Synergic prodegradative activity of Bicalutamide and trehalose on the mutant androgen receptor responsible for spinal and bulbar muscular atrophy.
Giorgetti E; Rusmini P; Crippa V; Cristofani R; Boncoraglio A; Cicardi ME; Galbiati M; Poletti A
Hum Mol Genet; 2015 Jan; 24(1):64-75. PubMed ID: 25122660
[TBL] [Abstract][Full Text] [Related]
14. Human androgen receptor mutation disrupts ternary interactions between ligand, receptor domains, and the coactivator TIF2 (transcription intermediary factor 2).
Lim J; Ghadessy FJ; Abdullah AA; Pinsky L; Trifiro M; Yong EL
Mol Endocrinol; 2000 Aug; 14(8):1187-97. PubMed ID: 10935543
[TBL] [Abstract][Full Text] [Related]
15. A novel androgen receptor-binding element modulates Cdc6 transcription in prostate cancer cells during cell-cycle progression.
Jin F; Fondell JD
Nucleic Acids Res; 2009 Aug; 37(14):4826-38. PubMed ID: 19520769
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of androgen receptor transcriptional activity as a novel mechanism of action of arsenic.
Rosenblatt AE; Burnstein KL
Mol Endocrinol; 2009 Mar; 23(3):412-21. PubMed ID: 19131511
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor-mediated repression of novel target genes.
Prescott J; Jariwala U; Jia L; Cogan JP; Barski A; Pregizer S; Shen HC; Arasheben A; Neilson JJ; Frenkel B; Coetzee GA
Prostate; 2007 Sep; 67(13):1371-83. PubMed ID: 17624924
[TBL] [Abstract][Full Text] [Related]
18. Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells.
Buchanan G; Need EF; Barrett JM; Bianco-Miotto T; Thompson VC; Butler LM; Marshall VR; Tilley WD; Coetzee GA
Mol Cell Endocrinol; 2011 Aug; 342(1-2):20-31. PubMed ID: 21664238
[TBL] [Abstract][Full Text] [Related]
19. Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes.
Dai Y; Ngo D; Jacob J; Forman LW; Faller DV
Carcinogenesis; 2008 Sep; 29(9):1725-33. PubMed ID: 18487222
[TBL] [Abstract][Full Text] [Related]
20. Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells.
Nakka M; Agoulnik IU; Weigel NL
Int J Biochem Cell Biol; 2013 Apr; 45(4):763-72. PubMed ID: 23270728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
